-
Mashup Score: 15Researchers modify drug to enter cells and treat pain - 12 month(s) ago
Altering the chemical properties of an anti-nausea drug enables it to enter an interior compartment of the cell and provide long-lasting pain relief, according to a new study led by researchers at NYU College of Dentistry’s Pain Research Center.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Ocaliva plus bezafibrate clears FDA orphan drug hurdle for primary biliary cholangitis - 12 month(s) ago
The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis. Obeticholic acid (Ocaliva, Intercept Pharmaceuticals) — a farnesoid X receptor agonist — was originally FDA approved for primary biliary cholangitis (PBC) in 2016 in combination with
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: #Ocaliva plus #bezafibrate clears @US_FDA orphan #drug hurdle for primary biliary #cholangitis @InterceptPharma #GITwitter #MedTwitter https://t.co/iPpEK8qmuG
-
-
Mashup Score: 0What We’re Reading: Blood Donation Guidelines Updated; Pfizer CEO Criticizes Drug Price Negotiations; Drug Shortages Worsened - 1 year(s) ago
The FDAs newest blood donation guidance may expand donation eligibility; Pfizer CEO anticipates lawsuits to stop US drug price plan; drug shortages have worsened and may increase even with the end of the COVID-19 public health emergency.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
What We’re Reading: #Blood Donation Guidelines Updated; @pfizer CEO Criticizes #Drug Price Negotiations; #Drug Shortages Worsened https://t.co/gAhgCrYTgU https://t.co/vryKJGeKFN
-
-
Mashup Score: 8Mechanisms underlying the antiarrhythmic effect of ARumenamide-787 in experimental models of the J wave syndromes and hypothermia - 1 year(s) ago
Background Brugada (BrS) and early repolarization syndromes (ERS), the so-called J wave syndromes (JWS), are associated with life-threatening ventricular arrhythmias. Pharmacologic approaches to therapy are currently limited. In this study, we examine the effects of ARumenamide-787 (AR-787) to suppress the electrocardiographic and arrhythmic manifestations of JWS and hypothermia. Methods We…
Source: journals.plos.orgCategories: General Medicine News, Latest HeadlinesTweet-
#Drug discovered by researchers shows potential life-saving results in treating cardiac arrhythmias @sfu @PLOSONE https://t.co/UpRpsfYxa3 https://t.co/5a2N318hAB
-
-
Mashup Score: 4A sharp increase in the price of gout drug colchicine led to lower use and poorer disease control, research suggests - 1 year(s) ago
Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to $190.49 in 2011. Out-of-pocket costs for patients who took the drug jumped more than four-fold from $7.37 to $39.49 over the same period.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
A sharp increase in the price of gout #drug colchicine led to lower use and poorer #diseasecontrol, research suggests @JAMAInternalMed https://t.co/DV01aWvIz3
-
-
Mashup Score: 4Chemotherapy drug reaches brain in humans for first time - 1 year(s) ago
A major impediment to treating the deadly brain cancer glioblastoma has been that the most potent chemotherapy can’t permeate the blood-brain barrier to reach the aggressive brain tumor.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Chemotherapy #drug reaches #brain in humans for first time @northwesternu @TheLancetOncol https://t.co/HTOIVoZk64
-
-
Mashup Score: 0What We’re Reading: EU Proposes Drug Overhaul; Potential New Rules From CMS; Paying New Antibiotic Developers - 1 year(s) ago
The European Union has proposed the biggest drug overhaul in 20 years, prompting industry conflict; CMS has proposed 2 new rules focused on increasing care access and quality of care for people enrolled in Medicaid and the Children’s Health Insurance Program; proposed legislation would promise $6 billion for treatments of drug-resistant infections that win approval.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
What We’re Reading: EU Proposes #Drug Overhaul; Potential New Rules From #CMS; Paying New #Antibiotic Developers Read more! https://t.co/UdNBGdCrYI https://t.co/CCFzDIs0Jz
-
-
Mashup Score: 8Study shows NIH investment in new drug approvals is comparable to investment by pharmaceutical industry - 1 year(s) ago
The National Institutes of Health (NIH) spent $187 billion for basic or applied research related to 354 of the 356 drugs approved by the FDA from 2010 to 2019, according to a new study from Bentley University’s Center for Integration of Science and Industry. The study, published in JAMA Health Forum, shows that the amount invested per approved drug by the NIH is comparable to that of reported…
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Study shows #NIH investment in new #drug approvals is comparable to investment by pharmaceutical industry @bentleyu @JAMAHealthForum https://t.co/lEDL2pZowI
-
-
Mashup Score: 0
Combination therapy with adalimumab plus low-dose methotrexate induced a two-fold reduction of treatment failure among pediatric patients with Crohn’s disease, according to research published in Gastroenterology. “Tumor necrosis factor inhibitors (TNFi), including infliximab and adalimumab, are a mainstay of pediatric Crohn’s disease therapy; however, non-response and loss of
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @AGA_Gastro: “The #evaluation and #comparison of additional strategies to further optimize response to #adalimumab, including proactive therapeutic #drug monitoring, warrant additional research," @MichaelKappel12 told @GoHealio #GI. https://t.co/ouFO1V0tdh
-
-
Mashup Score: 3
Objectives This study aims to examine the effects of the July 2018 worldwide valsartan recall and shortage on global trends of antihypertensive medication use in 83 countries. Methods A time-series analysis of monthly purchases of valsartan, other angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) across 83 countries from January 2017 to July 2020 was…
Source: BMJ OpenCategories: General Medicine News, Latest HeadlinesTweet-
Usage patterns amid hypertension #drug recall highlight vulnerability of global supply chains @BMJ_Open https://t.co/Ksj9gHJxTI https://t.co/KUuKBHYSu8
-
Researchers modify #drug to enter cells and treat #pain @PNASNews https://t.co/M01YxMMVx6